Table 1.
Characteristics of ovarian cancer patients.
| Characteristic | Cases N (%) |
|---|---|
| Age (mean ± SD, year) | Median: 52; Range: 26–78 |
| ≤52 | 62 (50.0) |
| >52 | 62 (50.0) |
| BMI (kg/m2) | 23.79 ± 4.02 |
| Menopause | |
| Yes | 76 (61.3) |
| No | 48 (38.7) |
| Pathologic type | |
| Serous | 82 (66.1) |
| Mucous and others | 42 (33.9) |
| Figo stage | |
| I–II | 51 (41.1) |
| III–IV | 73 (58.9) |
| Histologic grade | |
| G1-2 | 47 (37.9) |
| G3 and undifferentiated | 77 (62.1) |
| Residual disease | |
| <1 cm | 93 (75.0) |
| ≥1 cm | 31 (25.0) |
| Ascites volume (mL) | Median: 2,000; Range: 200–8,000 |
| <2,000 | 103 (83.1) |
| ≥2,000 | 21 (16.9) |
| Serum CA125 (U/mL) | Median: 573.35; Range: 14.10–67.62 |
| <573.35 | 74 (59.7) |
| ≥573.35 | 50 (40.3) |
| LN metastasis | |
| No | 76 (61.3) |
| Yes | 48 (38.7) |
| Response to BC after 2 cycles | |
| Response (CR, PR, and SD) | 63 (50.8) |
| Non-response (PD) | 61 (49.2) |
BC, bevacizumab plus single regimen chemotherapy; CR, Complete Response; PR, Partial Response; PD, Progressive Disease; SD, Stable Disease.